Pancreatic Cancer
One of the deadliest major cancers, often diagnosed late; most cases are driven by KRAS mutations.
Coverage of Pancreatic Cancer is holding steady : 3 signals on the latest tracked day, down 25% from its three-week baseline of 4, across 3 domains (down from 4 a week ago). That makes it the #165 most-covered of the 348 concerns we track.
What’s changed
6 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.
- Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis. · J Food Sci · 2026-09-01
- RASolute 302: Lessons Learned and the Road Ahead in Pancreatic Cancer. · Oncologist · 2026-08-28
- RevMed's RAS inhibitor gains landmark FDA approval for pancreatic cancer. · Nat Rev Drug Discov · 2026-08-27
- Pancreatic Cancer Breakthrough: FDA Approves New Drug Targeting Cancer-Causing KRAS Mutations - ABP Live English · KRAS Mutation Research (Google News) · 2026-08-29 · usually covers Kras Research
- FDA Approves Breakthrough Pancreatic Cancer Drug – An Oncologist Explains How Daraxonrasib Nearly Doubles Survival · University of Colorado Anschutz · 2026-08-28 · usually covers Precision Medicine
- DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer - OncLive · KRAS Mutation Research (Google News) · 2026-08-28 · usually covers Kras Research
What the reporting says
Across 101 tracked stories from 42 outlets, reporting on Pancreatic Cancer most often describes regulatory approvals (24), acquisition (2), launches or releases (2), military action (1), meetings or visits (1).
It shows up alongside KRAS (51), Pdac (17), G12d (11), FDA (32), Colorectal Cancer (9).
Two steps out: Lung Cancer (through KRAS, 51 shared stories on the weaker link); KRAS Mutant (through KRAS, 45 shared stories on the weaker link); AI (through FDA, 32 shared stories on the weaker link); Cder (through FDA, 32 shared stories on the weaker link).
Tracked since Mar 12, with coverage on 51 separate days — concentrated in Oncology and Pubmed Targeted.